The collaboration involves an exclusive licensing agreement, providing Stemline with global rights to develop and commercialise a novel KAT6A inhibitor, which is designed using Insilico’s artificial intelligence (AI) platform.
The molecule has shown positive results in preclinical studies, demonstrating a potent inhibition in multiple CDX and PDX models, as well as a good safety and efficacy profile. Insilico presented data on this development at the San Antonio Breast Cancer Symposium last month.
Insilico will receive $12m in an upfront payment from MenariniMenarini, as well as milestone payments with a combined value of more than $500m and sales royalties.
In September 2019, Insilico announced its AI-powered drug discovery system GENTRL, which was created in alliance with WuXi AppTec, a global open-access R&D and manufacturing platform, as well as professor Alán Aspuru-Guzik, who works in quantum computing and AI in chemistry.
In the announcement accompanying the agreement, Menarini CEO Elcin Barker Ergun said: “Having brought the first innovation in endocrine therapy after almost 20 years to the US and Europe with elacestrant for ER+/HER2- breast cancer patients, our aim is to further augment patient outcomes, and targeting KAT6A can potentially serve that in breast cancer and beyond.”
KAT6A proteins play a crucial role in regulating gene expression and are implicated in various cancers, including poor clinical outcomes of ER+/HER- breast cancers.
According to GlobalData’s Pharmaceutical Intelligence Center, PF-07248144 is currently being investigated in a Phase I clinical trial, with a Phase II trial planned.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.